May 20, 2013
Aduro Announces Poster Presentations of Phase 2 Pancreatic Cancer and Phase 1B Mesothelioma Clinical Trials at ASCO. Read it
here.
May 8, 2013
Aduro scientific advisory board member Daniel A. Portnoy elected to the National Academy of Sciences. Read it
here.
April 22, 2013
Aduro announces collaboration with Johns Hopkins University to evaluate
Aduro therapeutic melanoma vaccines in combination with anti-PD-1. Read
it
here.
April 5, 2013
Aduro announces upcoming presentations on oncology programs at American Association of Cancer Research meeting. Read it
here.
March 12, 2013
Aduro's acquisition of GVAX assets featured in article in
ddn magazine. Read it
here.
February 4, 2013
Aduro announces acquisition of GVAX assets from BioSante. Read it
here.
January 31, 2013
Aduro announces $6.5 million financing. Read it
here.
December 12, 2012
Aduro announces two presentations at Keystone meeting. Read it
here.
November 29, 2012
Aduro announces completion of enrollment in Phase 2 clinical trial. Read it
here.
November 27, 2012
Aduro BioTech listed as one of five companies to watch in Terrapin eBook on cancer vaccines. Read it
here.
October 16, 2012
Aduro's mesothelioma trial is featured on Asbestos.com, the website of The Mesothelioma Center. Read it
here.
October 2, 2012
Aduro announces first patient enrolled in mesothelioma clinical trial. Read it
here.
September 19, 2012
Aduro announces malaria vaccine collaboration with Protein Potential. Read it
here.
September 7, 2012
Aduro featured in article on immunotherapy research at the Providence Cancer Center in Portland. Read it
here.
September 6, 2012
Aduro awarded CDMRP grant for prostate cancer vaccine development. Read it
here.
February 7, 2012
Clinical results from Aduro’s Phase 1 trials published in
Clinical Cancer Research. Read it
here.
November 10, 2011
Aduro BioTech patent upheld by USPTO. Read it